Major research papers from NEJM in 2023

Here is a pleasant surprise, a collectors issue of NEJM year book 2023, is made available free (even for a non subscribers in its website) .It is fascinating to know how fast the Internal medicine has grown. For the busy cardiologists, this will a be refreshing reminder, that there are other important organs and specialties do exist in medicine , with equal breakthroughs and Innovations. It is indeed an amazing , whirlwind tour of medicine for all those who see medical science as single holistic specialty. It has articles, ranging from from simple clinical studies on postpartum hemorrhage (E-MOTIVE study) from deep inside Africa by Melinda Gate foundation, to Dupilumab for COPD, a stunning monoclonal antibody inhibitor of IL-4 for COPD exacerbations. Shortening tuberculosis treatment with a strategy involving initial treatment with an 8-week Bedaquiline-linezolid regimen (TRUNCATE-TB study) is also a revelation. Of-course, the mandatory cardiac topics do find a prominent place including the currently omnipresent drug GLP agonist Semaglutide for HFpEF (STEP-HFpEF study). Baxdrostat, an Aldosterone synthase antagonist for treatment-resistant Hypertension, appears promising (BrigHTN). Final message However, the crowning glory among all articles appear towards the end of the document, titled Combating misinformation as a core Function of Public Health. Let me share the link to this PDF document here. Hope it allows open access and there are no ...
Source: Dr.S.Venkatesan MD - Category: Cardiology Authors: Tags: Uncategorized 2023 review articles acc aha esc guidlines an Aldosterone synthase antagonist for Treatment-Resistant Hypertension Baxdrostat bmj E MOTIVE STUDY PPH lancet nejm Of-course semaglutide TRUNCATE TB Source Type: blogs